.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,201,920

« Back to Dashboard

Claims for Patent: 7,201,920

Title:Methods and compositions for deterring abuse of opioid containing dosage forms
Abstract: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
Inventor(s): Kumar; Vijai (Morris Plains, NJ), Dixon; David (Woodside, NY), Tewari; Divya (Suffern, NY), Wadgaonkar; Dilip B. (Suffern, NY)
Assignee: Acura Pharmaceuticals, Inc. (Palatine, IL)
Application Number:10/723,654
Patent Claims: 1. A therapeutic pharmaceutical composition comprising a mixture including (a) at least one opioid analgesic selected from the group consisting of alfentanil, buprenorphine, butorphanol, carfentanil, codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine, diprenorphine, etorphine, fentanyl, hydrocodone, hydromorphone, .beta.-hydroxy-3-methylfentanyl, levo-.alpha.-acetylmethadol, levorphanol, lofentanil, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, pethidine, prepoxyphene, remifentanil, sufentanil, tilidine, tramadol and a pharmaceutically acceptable salt thereof; (b) gel forming polyethylene oxide at about 3 to 40% by weight; (c) at least one disintegrant at about 2 to 25% by weight, selected from the group consisting of crospovidone, sodium starch glycolate, and croscarmellose sodium; and (d) a nasal tissue irritant, wherein the composition functions such that less than about 50% of the total amount of opioid analgesic in the composition is recovered when about 490 mg. of the composition is contacted with 15 ml of water.

2. The therapeutic pharmaceutical composition of claim 1, further comprising an emetic.

3. The therapeutic pharmaceutical composition of claim 1, wherein the gel forming polyethylene oxide has an average molecular weight ranging from about 300,000 to about 5,000,000.

4. The therapeutic pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in unit dose form.

5. The therapeutic pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in a suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form.

6. The therapeutic pharmaceutical composition of claim 1, wherein the analgesic is present in an amount of about 0.5 to about 25 percent by weight.

7. The therapeutic pharmaceutical composition of claim 1, wherein the analgesic is hydrocodone or a pharmaceutically acceptable salt thereof.

8. The therapeutic pharmaceutical composition of claim 1, wherein the analgesic is oxycodone or a pharmaceutically acceptable salt thereof.

9. The therapeutic pharmaceutical composition of claim 8, wherein the disintegrant is crospovidone.

10. The therapeutic pharmaceutical composition of claim 1, wherein the analgesic is morphine or a pharmaceutically acceptable salt thereof.

11. The therapeutic pharmaceutical composition of claim 1, wherein the analgesic is codeine or a pharmaceutically acceptable salt thereof.

12. The therapeutic pharmaceutical composition of claim 1, wherein the analgesic is hydromorphone or a pharmaceutically acceptable salt thereof.

13. The therapeutic pharmaceutical composition of claim 1, wherein the analgesic is propoxyphene or a pharmaceutically acceptable salt thereof.

14. The therapeutic pharmaceutical composition of claim 1, wherein the analgesic is tramadol or a pharmaceutically acceptable salt thereof.

15. The therapeutic pharmaceutical composition of claim 1, wherein the analgesic comprises meperidine or a pharmaceutically acceptable salt thereof.

16. The therapeutic pharmaceutical composition of claim 1, wherein the analgesic is methadone or a pharmaceutically acceptable salt thereof.

17. The therapeutic pharmaceutical composition of claim 1, wherein the analgesic is pentazocine or a pharmaceutically acceptable salt thereof.

18. The therapeutic pharmaceutical composition of claim 1, wherein the disintegrant is crospovidone.

19. A therapeutic pharmaceutical composition comprising a mixture including (a) at least one opioid analgesic selected from the group consisting of alfentanil, buprenorphine, butorphanol, carfentanil, codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine, diprenorphine, etorphine, fentanyl, hydrocodone, hydromorphone, .beta.-hydroxy-3-methylfentanyl, levo-.alpha.-acetylmethadol, levorphanol, lofentanil, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, pethidine, propoxyphene, remifentanil, sufentanil, tilidine, tramadol and a pharmaceutically acceptable salt, thereof; (b) gel forming polyethylene oxide at about 3 to 40% by weight; (c) a surfactant at about 1 to 10% by weight; (d) at least one disintegrant at about 2 to 25% by weight, wherein the disintegrant is selected from the group consisting of crospovidone, sodium starch glycolate, and croscarmellose sodium; and (e) wherein the composition functions such that less than about 50% of the total amount of opioid analgesic in the composition is recovered when about 490 mg. of the composition is contacted with 15 ml of water.

20. The therapeutic pharmaceutical composition of claim 19, further comprising an emetic.

21. The therapeutic pharmaceutical composition of claim 19, wherein the gel forming polyethylene oxide has an average molecular weight ranging from about 300,000 to about 5,000,000.

22. The therapeutic pharmaceutical composition of claim 19, wherein the pharmaceutical composition is in unit dose form.

23. The therapeutic pharmaceutical composition of claim 19, wherein the pharmaceutical composition is in a suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form.

24. The therapeutic pharmaceutical composition of claim 19, wherein the analgesic is present in an amount of about 0.5 to about 25 percent by weight.

25. The therapeutic pharmaceutical composition of claim 19, wherein the analgesic is hydrocodone or a pharmaceutically acceptable salt thereof.

26. The therapeutic pharmaceutical composition of claim 19, wherein the analgesic is oxycodone or a pharmaceutically acceptable salt thereof.

27. The therapeutic pharmaceutical composition of claim 26, wherein the disintegrant is crospovidone.

28. The therapeutic pharmaceutical composition of claim 19, wherein the analgesic is morphine or a pharmaceutically acceptable salt thereof.

29. The therapeutic pharmaceutical composition of claim 19, wherein the analgesic is codeine or a pharmaceutically acceptable salt thereof.

30. The therapeutic pharmaceutical composition of claim 19, wherein the analgesic is hydromophone or a pharmaceutically acceptable salt thereof.

31. The therapeutic pharmaceutical composition of claim 19, wherein the analgesic is propoxyphene or a pharmaceutically acceptable salt thereof.

32. The therapeutic pharmaceutical composition of claim 19, wherein the analgesic is tramadol or a pharmaceutically acceptable salt thereof.

33. The therapeutic pharmaceutical composition of claim 19, wherein the analgesic is meperidine or a pharmaceutically acceptable salt thereof.

34. The therapeutic pharmaceutical composition of claim 19, wherein the analgesic is methadone or a pharmaceutically acceptable salt thereof.

35. The therapeutic pharmaceutical composition of claim 19, wherein the analgesic is pentazocine or a pharmaceutically acceptable salt thereof.

36. The therapeutic pharmaceutical composition of claim 19, wherein the disintegrant is crospovidone.

37. A therapeutic pharmaceutical composition comprising: a mixture including (a) at least one opioid analgesic selected from the group consisting of alfentanil, buprenorphine, butorphanol, carfentanil, codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine, diprenorphine, etorphine, fentanyl, hydrocodone, hydromorphone, .beta.-hydroxy-3-methylfentanyl, levo-.alpha.-acetylmethadol, levorphanol, lofentanil, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, pethidine, propoxyphene, remifentanil, sufentanil, tilidine, tramadol and a pharmaceutically acceptable salt thereof; (b) gel forming polyethylene oxide at about 3 to about 40 percent by weight; (c) at least one disintegrant at about 2 to 25 percent by weight wherein the disintegrant is selected from the group consisting of crospovidone, sodium starch glycolate, and croscarmellose sodium; and (d) sodium lauryl sulfate at about 1 to 10 percent by weight.

38. The therapeutic pharmaceutical composition of claim 37, further comprising an emetic.

39. The therapeutic pharmaceutical composition of claim 37, wherein the gel forming polyethylene oxide has an average molecular weight ranging from about 300,000 to about 5,000,000.

40. The therapeutic pharmaceutical composition of claim 37, wherein the pharmaceutical composition is in unit dose form.

41. The therapeutic pharmaceutical composition of claim 37, wherein the pharmaceutical composition is in a suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form.

42. The therapeutic pharmaceutical composition of claim 37, wherein the analgesic is present in an amount of about 0.5 to about 25 percent by weight.

43. The therapeutic pharmaceutical composition of claim 37, wherein the analgesic is hydrocodone or a pharmaceutically acceptable salt thereof.

44. The therapeutic pharmaceutical composition of claim 37, wherein the analgesic is oxycodone or a pharmaceutically acceptable salt thereof.

45. The therapeutic pharmaceutical composition of claim 44, wherein the disintegrant is crospovidone.

46. The therapeutic pharmaceutical composition of claim 37, wherein the analgesic is morphine or a pharmaceutically acceptable salt thereof.

47. The therapeutic pharmaceutical composition of claim 37, wherein the analgesic is codeine or a pharmaceutically acceptable salt thereof.

48. The therapeutic pharmaceutical composition of claim 37, wherein the analgesic is hydromorphone or a pharmaceutically acceptable salt thereof.

49. The therapeutic pharmaceutical composition of claim 37, wherein the analgesic is propoxyphene or a pharmaceutically acceptable salt thereof.

50. The therapeutic pharmaceutical composition of claim 37, wherein the analgesic is tramadol or a pharmaceutically acceptable salt thereof.

51. The therapeutic pharmaceutical composition of claim 37, wherein the analgesic is meperidine or a pharmaceutically acceptable salt thereof.

52. The therapeutic pharmaceutical composition of claim 37, wherein the analgesic is methadone or a pharmaceutically acceptable salt thereof.

53. The therapeutic pharmaceutical composition of claim 37, wherein the analgesic is pentazocine or a pharmaceutically acceptable salt thereof.

54. The therapeutic pharmaceutical composition of claim 37, wherein the disintegrant is crospovidone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc